GARDP Establishes India R&D Advisory Group to Boost Capacity and Support Future Development

8 Sep 2020

The Global Antibiotic Research and Development Partnership (GARDP) has established an India Advisory Group for research and development to maximize Indian knowledge and capacity in support of GARDP’s work to develop new treatments for drug-resistant infections, for every person who needs them. This will include the development of networks and defining strategic priorities for research and development, as well as access, in India and internationally.

The objective of the advisory group is to support the development of new treatments by:

  • Leveraging and strengthening research and development capacity within country (including the Lifesciences and pharmaceutical industry)
  • Building partnerships and networks for mutual benefit
  • Leveraging funding to optimize investments in infectious disease research and development and access
  • Using the knowledge, expertise, and international networks of GARDP to benefit research and development programmes and partnerships within India
  • Interfacing with Regulators to sensitize them on best practices including global data harmonization
  • Interfacing with Government of India to help create sustainable market mechanisms to support AMR Innovation

The India Advisory Group includes:

  • Dr Anand Anandkumar, co-founder and CEO, Bugworks Research India Pvt. Ltd
  • Prof Y K Gupta, Principal Adviser (Project), THSTI – DBT ,GOI
  • Dr Harish Iyer, Senior Advisor, R&D and Life Sciences Partnerships, BMGF
  • Dr Shrishendu Mukherjee, Mission Director, BIRAC
  • Dr Camilla Rodrigues, Consultant Microbiology & Chairperson Infection Control Committee, Hinduja Hospital
  • Dr Zakir Thomas, in his individual capacity.
  • Dr Kamini Walia, Scientist F – Division of Epidemiology and Communicable Diseases, ICMR
  • Dr Suman Rijal, DNDi India Director will be the Secretary of this group.